Han, Kim and Oh acquired 0.91% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for approximately KRW 950 million.
May 08, 2018
Share
Han, Kim and Oh acquired 0.91% stake in SunBio,Inc. (XKON:A067370) from Kangpyung Telecom Co., Ltd. for approximately KRW 950 million on April 27, 2018. A total of 0.07 million shares will be transferred for KRW 13,500 as part of the deal. After the deal, Kangpyung Telecom will hold 0.31 million shares in SunBio,Inc from 0.38 million shares held earlier. Kim acquired 0.03 million shares, Han acquired 0.02 million shares and Oh acquired 0.02 million shares as part of the deal.
Han, Kim and Oh completed the acquisition of 0.91% stake in SunBio,Inc. (XKON:A067370) from Kangpyung Telecom Co., Ltd. on April 27, 2018.
SunBio,Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. The Company operates its business through three segments. The Polyethylene Glycol (PEG) Derivative Product business segment is involved in the manufacturing and sale of PEG derivative products. The PEG derivatives are intermediate materials used in dermal filler, drug delivery systems, hydrogel, and nanotechnology. The Biosimilar Business segment is involved in the manufacturing and sale of royalty and technology transfer products. The main products are neutropenia treatment products, and hepatitis C treatment products. The New Drug Development Business segment is involved in the development of oxygen carriers, artificial blood, stroke aid agents, cartilage synovial fillers, dry mouth treatment drugs, and long-term preservatives.
SUNBIO,INC. 
